Novel imaging modalities in gynecologic cancer.
Novel imaging modalities continue to emerge in medicine, and the advent of (18)F-fluorodeoxyglucose-positron emission tomography (FDG-PET) has had a significant impact in the imaging of gynecologic malignancies. In cervical cancer, FDG-PET has excellent sensitivity and specificity for evaluation of initial disease, as well as assessment of post-treatment response and long-term surveillance. In ovarian cancer, FDG-PET can be a useful tool in assessing recurrent disease, especially in the setting of a rising cancer antigen-125 with a negative or equivocal CT or MRI. In uterine cancer, FDG-PET has been investigated in evaluating the extent of disease including nodal metastases, and in assessing recurrence. This article reviews novel imaging modalities in gynecologic cancer, with a special focus on FDG-PET/CT.
Brooks
Rebecca A
RA
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine, Box 8064, Saint Louis, MO 63110, USA.
Powell
Matthew A
MA
D005260:Female; D019788:Fluorodeoxyglucose F18; D005833:Genital Neoplasms, Female / Q000000981:diagnostic imaging*; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging; D010051:Ovarian Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18